Research Indicates Potential Connection Between Prenatal Medication
In a groundbreaking exploration that promises to reshape the understanding of prenatal medication safety, researchers at the University of Nebraska Medical Center (UNMC) have unveiled compelling evidence linking prenatal exposure to certain commonly prescribed medications to an increased risk of autism spectrum disorder (ASD) in children. This comprehensive study, published in the prestigious journal Molecular Psychiatry, harnesses the power of a large dataset including more than six million maternal and child health records from the Epic Cosmos database. This large cohort represents approximately one-third of all births in the United States between 2014 and 2023, providing a solid basis for uncovering subtle but meaningful associations.
The crux of this pioneering work lies in the identification of a class of drugs known to impair sterol biosynthesis, a critical biochemical pathway responsible for the production and regulation of cholesterol. Unlike previous research efforts that classified prenatal medications based on their clinical indications, this study took a new approach, grouping medications based on their common biochemical interference. These sterol biosynthesis inhibitor medications (SBIMs) include a wide range of medications commonly prescribed during pregnancy, including antidepressants, antipsychotics, anxiolytics, beta-blockers, and statins. Among the 14 SBIMs reviewed, notable examples include fluoxetine, sertraline, atorvastatin, and propranolol, each of which is prescribed millions of times per year in the United States.
The analysis reveals a striking statistical correlation: Pregnant people who were prescribed at least one SBIM faced a 1.47 times higher likelihood of giving birth to a child later diagnosed with ASD. Even more alarming, this risk has increased alongside the number of these drugs prescribed. Co-prescription of multiple SBIMs compounded the threat, resulting in a 2.33 times higher risk when four or more such medications were administered simultaneously. The magnitude of these findings requires urgent attention, especially as prenatal exposure to SBIM increased significantly over the nearly ten-year study period, from 4.3% of pregnancies in 2014 to 16.8% in 2023.
Understanding why disruption of sterol biosynthesis exerts profound effects on neurodevelopment requires further investigation into the role of cholesterol in fetal growth. Cholesterol is essential for the development of the fetal brain and other critical organs, serving as a fundamental component of cell membranes, a precursor to the synthesis of steroid hormones, and a modulator of signaling pathways guiding neuronal differentiation. The fetal brain itself begins autonomous production of sterols around 19 to 20 weeks of gestation, a critical period for synaptogenesis and circuit formation. Intriguingly, inherited mutations affecting this pathway lead to devastating developmental disorders such as Smith-Lemli-Opitz syndrome, in which up to 75% of affected children exhibit ASD symptoms. The present study suggests that pharmacological interference of the same pathway may recapitulate some aspects of this vulnerability, highlighting the delicate balance required for healthy brain maturation.
Although the implicated medications are widely used and often essential for managing chronic diseases in pregnant women, these findings prompt a reassessment of their safety profiles during gestation. The authors emphasize that the results should not arouse fear or lead to abrupt cessation of prescribed treatments without medical advice; rather, they advocate increased vigilance on the part of health care providers. The study highlights the urgent need to examine the biochemical imprints of existing and new pharmaceuticals on sterol metabolism, particularly as prescribing patterns evolve and the prevalence of polypharmacy during pregnancy increases.
The implications extend beyond individual prescriptions to public health strategy. The researchers propose several critical avenues for future actions, such as building a comprehensive pharmacopoeia identifying sterol inhibitory agents and integrating assessments of sterol metabolism into the drug development pipeline. Better education of clinicians about the neurodevelopmental risks associated with sterol disruption during pregnancy could inform prescribing decisions, facilitating safer alternatives when available or minimizing combined exposures. Additionally, identifying pregnant individuals with inherent genetic susceptibilities to sterol metabolism could tailor risk mitigation efforts, thereby enabling personalized therapeutic strategies.
This landmark investigation represents a significant advance in the field of perinatal pharmacology and neurodevelopmental research. By leveraging the unprecedented scale of electronic health record data, the UNMC team transcended traditional research boundaries, highlighting a biochemical mechanism that may underlie part of the etiology of ASD linked to environmental exposures. Their findings call for a multidisciplinary response involving molecular biology, clinical pharmacology, genetics and public health and could catalyze innovative approaches to safeguard fetal brain health in the context of necessary maternal medical treatment.
The study also draws attention to broader biomedical and ethical considerations. Balancing maternal health needs and fetal safety requires nuanced clinical judgment, informed by emerging evidence like this. It highlights the importance of comprehensive prenatal care and the integration of precision medicine principles that consider drug mechanisms at the biochemical level. Ultimately, the research paves the way for more informed and safer medical prescribing during pregnancy, with the potential to reduce the burden of ASD and improve child neurodevelopmental outcomes on a population level.
As the scientific community digests this knowledge, there remains a clear imperative for further research. Research into the specific molecular perturbations caused by individual SBIMs, their dose-response relationships, timing of exposure during gestation, and interaction with genetic variants will be essential. Furthermore, exploring potential protective strategies or complementary therapies to counteract sterol biosynthesis inhibition could open therapeutic avenues. This study marks a critical first step toward understanding the complex interplay between prenatal environmental factors and long-term neurodevelopment.
UNMC’s leadership in this endeavor reflects its commitment to innovative, patient-centered research. The collaboration between pediatricians, biostatisticians and neurodevelopmental experts, supported by internal resources and foundations, showcases the power of interdisciplinary science to address pressing public health challenges. Their engagement with the Epic Cosmos platform illustrates how large-scale digital health data can power groundbreaking discoveries with lasting impact.
In summary, the revelation that sterol biosynthesis inhibitor drugs commonly prescribed during pregnancy may increase the risk of autism invites a paradigm shift in perinatal pharmacotherapy. This highlights the need for scientific, clinical, and policy efforts to ensure that medications protecting maternal well-being do not inadvertently compromise fetal neurodevelopment. Continued vigilance, research and innovation will be essential to unravel and mitigate these complex risks, leading to progress towards a healthier future for mothers and their children.
Research subject: People
Article title: Study suggests link between prenatal exposure to certain medications and increased risk of autism
News publication date: 16-Apr-2026
Web references: https://www.nature.com/articles/s41380-026-03610-7
Image credits: Kiley Cruse and Chuck Koster
Keywords: Human health, Developmental disorders, Autism spectrum disorders, Prenatal medications, Inhibition of sterol biosynthesis, Cholesterol metabolism, Neurodevelopment, Perinatal pharmacology, Electronic health records, Public health
Tags: beta-blockers in pregnancy and neurodevelopmentbiochemical pathways affecting fetal brain developmentEpic Cosmos databasematernal-infant dataimpact of antipsychotics on fetal developmentlarge-scale epidemiological study of autismmaternal and child health record analysismolecular psychiatry research on prenatal exposureprenatal antidepressant use and ASDantenatal drug safety and spectrum disorders autismprenatal drug exposure and risk of autismstatins and prenatal safety concernsesterol biosynthesis inhibitor drugs during pregnancy
